We are thrilled to announce that the recent Phase III Sorafenib Desmoid Tumor Study, has been named by ASCO as one of the top breakthroughs in Oncology in 2018. Named as an “Advance of the Year”, the desmoid study is showcased with others showing “major breakthroughs in clinical cancer research and care.”
The American Society of Clinical Oncology is the world’s leading professional organization of researchers and clinicians who treat people who have cancer. Per ASCO, “rare cancers account for approximately 20% of all cancers diagnosed each year, and incidence rates vary worldwide. Progress has historically lagged behind the achievements made in more common cancers; however, five major studies this past year [including the Sorafenib Desmoid study] offer significant steps forward, making this a notable year for advances in rare cancers.”
We congratulate DTRF Scientific Advisor, Dr. Mrinal Gounder, for his leadership as Principal Investigator of the trial.
Read more in ASCO Special Article: http://ascopubs.org/doi/10.1200/JCO.18.02037
The Sorafenib study has also been highlighted in Conquer Cancer – https://www.conquer.org/advancing-clinical-research